Mayne Pharma recently announced the U.S. launch of temozolomide capsules, 5mg, 20mg, 100mg, 140mg, 180mg and 250mg, which is a generic version of branded Temodar®. Temozolomide capsules are indicated for the treatment of adult patients with newly diagnosed cancerous brain tumors known as glioblastoma multiform concomitantly with radiotherapy and then as maintenance treatment. Temozolomide capsules had U.S. sales of approximately US$150m for the 12 months ending 30 September 2016, according to IMS Health. Mayne Pharma will distribute the drug on behalf of its partner, IDT Australia Ltd (IDT), which developed the product and is manufacturing the product. “Since entering the United States in 2012, Mayne Pharma has aggressively expanded its product portfolio, through internal product development, strategic acquisition, in-licensing and working collaboratively with partners like IDT”, said Stefan Cross, president of Mayne Pharma USA. “Mayne Pharma now directly markets more than 50 products and we have a growing pipeline of more than 40 generic and branded drug products targeting U.S. markets with IMS Health sales greater than $6 billion.”